Ardisiacrispin B, a natural triterpenoid saponins, suppresses dextran sulfate sodium-induced inflammatory bowel disease by rebalancing the gut microbiota and Th17/Treg of mice.

Researchers have discovered that a natural compound called Ardisiacrispin B (AB), derived from plant-based saponins, may offer significant benefits for people suffering from inflammatory bowel disease (IBD). In this study, scientists tested AB on mice with chemically-induced IBD to understand how it might help reduce inflammation and heal the digestive tract.

The results were promising. Mice treated with AB experienced less weight loss, reduced disease severity, and better preservation of colon length compared to untreated mice. The compound worked through multiple mechanisms: it strengthened the intestinal barrier by increasing protective proteins that keep the gut lining intact, reduced inflammatory markers like IL-1β, IL-6, and TNF-α, and blocked several inflammation-promoting pathways in the body.

Interestingly, AB also improved the balance of gut bacteria, increasing beneficial species like Akkermansia while decreasing harmful bacteria such as Bacteroides and Helicobacter. Additionally, the compound helped restore immune system balance by regulating specific immune cells called Th17 and Treg cells, which play crucial roles in inflammation and immune tolerance.

While this research involved mice rather than humans, it suggests that natural triterpenoid saponins like AB could eventually become part of integrative treatment approaches for IBD. Traditional Chinese Medicine practitioners have long used herbal compounds containing similar saponins for digestive disorders, and this study provides scientific evidence supporting their therapeutic potential. If you're interested in exploring herbal medicine or acupuncture as complementary approaches to IBD management, consult with a qualified, licensed practitioner who can develop an individualized treatment plan.

This preclinical study investigated Ardisiacrispin B (AB), a triterpenoid saponin, in a dextran sulfate sodium (DSS)-induced IBD mouse model. AB administration significantly reduced disease activity index scores, prevented colon shortening, and ameliorated histopathological damage. Mechanistically, AB enhanced intestinal barrier integrity by upregulating tight junction proteins (ZO-1, Occludin, claudin-1) and MUC2, while reducing permeability markers (ET-1, DAO). The compound suppressed pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and inhibited JAK2/STAT3 and TLR4/MyD88/NF-κB signaling pathways. 16S rRNA sequencing revealed AB rebalanced gut microbiota, increasing Akkermansia and decreasing pathogenic Bacteroides and Helicobacter. Notably, AB restored Th17/Treg immune balance by reducing IL-17, elevating IL-10, IL-22, and TGF-β, and normalizing Th17/Treg ratios in blood, mesenteric lymph nodes, and spleen. These findings position AB as a promising multi-targeted therapeutic candidate for IBD through coordinated regulation of barrier function, microbiome composition, and immune homeostasis.